全球转化科学和临床药理学CRO安渡生物完成B轮融资

Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies, today announced the completion of Series B financing to support its further global expansion. The financing was co-led by Sequoia Capital and GL Ventures (venture capital arm of Hillhouse Group), two prominent venture capital and private equity firms specialized in technology and healthcare industries. Other participating investors include CMB International Capital, MSA Capital, and Series A lead VC Co-win Ventures.  Amador Bioscience announced the completion of Series B financing co-led by Sequoia Capital and GL Ventures. co-led by Sequoia Capital and GL Ventures." data-twitter-share-url="https://www.prnewswire.com/news-releases/institutional-investors-co-led-series-b-financing-of-amador-bioscience-a-global-translational-sciences-and-clinical-pharmacology-cro-301386617.html"> Tweet this According to Dr. Bing Wang, CEO and Chairman of the Board, " Amador Bioscience's mission is to leverage our extensive industry experience and ecosystem to provide global-standard services for efficient development of novel drugs. As demonstrated by the company logo, Amador strives to bridge across nonclinical and clinical development stages, and across China and other countries. As a global vendor for multinational pharmaceutical companies, Amador duly keeps the confidentiality and non-competition obligations for global clients. We are very grateful for the trust and support of Sequoia and Hillhouse, co-leads of Series B financing. Through effective collaboration with biopharmaceutical companies, we aim to establish Amador as one of the leading global partners for successful new drug development."
（以上内容由医药魔方AI生成）